Stockreport

Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' [Seeking Alpha]

Seres Therapeutics, Inc.  (MCRB) 
Last seres therapeutics, inc. earnings: 11/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.serestherapeutics.com
PDF This sale also helped them extend their runway into Q2 2026 after a 25% workforce reduction. Their next value driver will come with SER-155's Phase 2 for gut-driven b [Read more]